This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Other drugs used to control the ventricular rate in AF

Authoring team

Digoix may also be used in the control of ventricular rate in atrial fibrillation:

  • beta-blockers:
    • may be used alone or in conjunction with digoxin
    • reduce ventricular rate at all levels of exercise
    • do not increase exercise capacity

  • verapamil and diltiazem:
    • reduce ventricular rate at rest and during exercise
    • improve exercise capacity in 7-8% of patients with AF
    • verapamil may be combined with digoxin

NICE suggest:

  • offer either a standard beta-blocker (that is, a beta-blocker other than sotalol) or a rate-limiting calcium-channel blocker as initial monotherapy to people with atrial fibrillation who need drug treatment as part of a rate control strategy. Base the choice of drug on the person's symptoms, heart rate, comorbidities and preferences when considering drug treatment

  • digoxin should only be considered as monotherapy if
    • the person does no or very little physical exercise or
    • other rate-limiting drug options are ruled out because of comorbidities or the person's preferences

  • if monotherapy does not control symptoms, and if continuing symptoms are thought to be due to poor ventricular rate control, consider combination therapy with any 2 of the following:
    • a beta-blocker
    • diltiazem
    • digoxin

  • do not offer amiodarone for long-term rate control

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.